Follow us on:

Ilika Stereax device sales don’t have to wait till end of approval period (VIDEO)

Ilika plc (LON:IKA) CEO Graeme Purdy joins DirectorsTalk Interviews to discuss an update its on trading, Stereax® manufacturing, and Goliath product development.

Graeme addresses some concerns around the weighting now to medical devices where commercial sales are set to commence at the end of the (H2/2023) period, the visible lack of contracts, the interest Ilika is getting for Goliath, its strategic partners and whether it would it be better to complete the scale up and then look to spin or sell that part of the business.

Ilika is a pioneer in solid state battery technology, enabling solutions for applications such as Industrial IoT, MedTech, EV and Consumer Electronics.

You might also enjoy reading Ilika Plc Leading the Charge in Solid-State Battery Innovation, Panmure Liberum note 'Considerable Upside'

Find more news, interviews, share price & company profile here for:Ilika

Share this interview

Other Interviews

More News

Ilika Plc Appoint Dr. Monika Biddulph with 20+ years of ARM IP licensing experience January 16, 2019
Ilika Plc Successfully passes annual ISO9001:2015 surveillance audit December 11, 2018
Ilika plc Appoint Keith Jackson as Chairman and form Technology Advisory Board November 29, 2018
Ilika Plc Manufacturing agreement for Stereax® with Semefab Ltd November 20, 2018
INTERVIEW: Ilika plc Increased energy density and perpetual power packs November 8, 2018
Ilika Plc Record Energy Density Achieved for Stereax November 7, 2018
Ilika plc Significant improvement in power cell performance November 1, 2018
INTERVIEW: Ilika plc Tier 1 supplier to hostile environment test Stereax P180 October 22, 2018
Ilika Plc Ship samples of Stereax® P180 batteries to Tier 1 automotive supplier October 18, 2018
INTERVIEW: Ilika plc PowerDrive Line Collaboration October 8, 2018

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.